ArticleBladder (San Francisco, Calif.)2025
Seven cases of robot-assisted radical cystectomy with Bordeaux neobladder: A clinical observation.
Article in Bladder (San Francisco, Calif.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bladder cancer (BCa) poses a significant global health burden with mounting incidence and mortality rates. Effective treatment strategies are urgently needed to alleviate the disease burden and improve patients' quality of life (QoL). Objective: This study aimed to evaluate the efficacy of robot-assisted radical cystectomy (RARC) plus the Bordeaux robotic intracorporeal orthotopic neobladder (riONB) technique for the treatment of BCa. Methods: We retrospectively analyzed clinical data from seven male patients who had undergone RARC with Bordeaux riONB between June 2023 and November 2024. The median age was 68 years, and the median body mass index was 24.2 kg/m Results: The median operation time lasted for 583 min, with a median estimated blood loss of 375 mL and a median post-operative hospital stay of 10 days. Pathological results showed that five patients (71.4%) were at stage ≥T2. According to the Clavien-Dindo classification, six patients (85.7%) had grade I - II complications. At 6 months post-surgery, the average maximum cystometric capacity measured 397 mL, the average post-void residual urine volume was 29 mL, the average urine flow rate was 5.6 mL/s, and the incontinence-QoL score was 85. Daytime urinary control was good in five patients (71.4%), and nighttime control was good in three patients (42.9%). Conclusion: The results indicate that RARC + Bordeaux riONB is a safe and effective surgical option for BCa, accomplishing good patient recovery and significant clinical efficacy. However, the study was subject to limitations of a small sample size and a short follow-up period. Further research with larger cohorts and longer follow-up is warranted to confirm these findings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.